The Future
of Cancer Diagnostics
OraLiva Inc. provides noninvasive, painless, reliable, clinically validated AI linked diagnostics for the detection of oral cancer and oral dysplasia. A point of care/near patient testing platform technology for a broad range of cancers.
Join Dr. McDevitt on the Prime Movers Lab Podcast on March 28, 2023 at 3pm ET for a deep dive in diagnostics trends!
Register online on this Link or by requesting a link on our Contact Us Page!
OraLiva Inc. has developed
a next generation programmable single
cell cytology platform that is suitable for early cancer detection.
This agile platform allows for rapid expansion to a large menu of tests. In collaboration with the McDevitt Laboratory at NYU, large clinical studies have been completed to define signatures of early disease. OraLiva Inc’s first application is targeted for Q3 2023 in the area of oral cancer.
OraLiva Inc. saves lives and costs through early oral cancer detection.
Oral cancer is one of the most expensive cancers and one with the poorest outcomes.
C-AIIDE:
Cytology
Artificial
Intelligence
IDEntification
OraLiva Inc’s C-AIIDE is the first portable, programmable cytology platform for use at point of care.
